Vanzacaftor and Mitapivat: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mitapivat
Vanzacaftor
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced vanzacaftor exposure and reduced efficacy of vanzacaftor
Interaction Deep Dive
Coadministration of vanzacaftor with strong or moderate CYP3A inducers is not recommended as it may reduce vanzacaftor exposure, which may reduce vanzacaftor efficacy. In a drug interaction study, coadministration of vanzacaftor/tezacaftor/deutivacaftor combination (20/100/250 mg once daily) with the strong CYP3A inducer rifAMPin 600 mg once daily significantly reduced vanzacaftor AUC by 18% and Cmax of by 22%, it also reduced deutivacaftor AUC by 10% and Cmax by 20%1.
Why it happens (mechanism)
Induction of CYP3A-mediated metabolism of vanzacaftor
Literature reports
1 report — tap to read
a) In a drug interaction study, coadministration of vanzacaftor/tezacaftor/deutivacaftor combination (20/100/250 mg once daily) with the strong CYP3A inducer rifAMPin 600 mg once daily significantly reduced vanzacaftor AUC by 18% and Cmax of by 22%, it also reduced deutivacaftor AUC by 10% and Cmax by 20% 1.
Common questions
Can I take Vanzacaftor and Mitapivat together?
Reduced vanzacaftor exposure and reduced efficacy of vanzacaftor Always confirm with your pharmacist or prescriber before making any change.
How serious is the Vanzacaftor and Mitapivat interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Vanzacaftor or Mitapivat need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ALYFTREK(R) oral tablets, vanzacaftor, tezacaftor, and deutivacaftor oral tablets. Vertex Pharmaceuticals Incorporated (per FDA), Boston, MA, 2024. DailyMed
Keep reading about Mitapivat
Keep reading about Vanzacaftor
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist